Perceptive Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Perceptive Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,663	Closed	-$726K	–	156
2021 Q4	$726K	Hold	4,663	–	–	0.01%	139
2021 Q3	$934K	Hold	4,663	–	–	0.01%	135
2021 Q2	$1.19M	Hold	4,663	–	–	0.02%	142
2021 Q1	$1.24M	Hold	4,663	–	–	0.02%	131
2020 Q4	$1.72M	Hold	4,663	–	–	0.02%	131
2020 Q3	$1.14M	Hold	4,663	–	–	0.02%	116
2020 Q2	$1.34M	Hold	4,663	–	–	0.02%	108
2020 Q1	$951K	Hold	4,663	–	–	0.02%	96
2019 Q4	$2.08M	Hold	4,663	–	–	0.04%	87
2019 Q3	$1.43M	Hold	4,663	–	–	0.04%	85
2019 Q2	$1.48M	Hold	4,663	–	–	0.03%	87
2019 Q1	$1.96M	Hold	4,663	–	–	0.06%	75
2018 Q4	$1.42M	Sell	4,663 -593	-11%	-$192K	0.05%	77
2018 Q3	$1.89M	Hold	5,256	–	–	0.05%	86
2018 Q2	$1.92M	Hold	5,256	–	–	0.05%	88
2018 Q1	$1.55M	Hold	5,256	–	–	0.04%	97
2017 Q4	$2.2M	Hold	5,256	–	–	0.07%	89
2017 Q3	$1.73M	Hold	5,256	–	–	0.07%	95
2017 Q2	$1.25M	Hold	5,256	–	–	0.06%	91
2017 Q1	$1.8M	Hold	5,256	–	–	0.1%	87
2016 Q4	$1.84M	Buy	5,256 +925	+21%	+$339K	0.13%	83
2016 Q3	$1.74M	Buy	4,331 +834	+24%	+$426K	0.11%	90
2016 Q2	$2.08M	Hold	3,497	–	–	0.14%	86
2016 Q1	$1.76M	Buy	+3,497	New	+$1.74M	0.15%	89

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors's EIGR Position: Q1 2022 in Review

Perceptive Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 4,663 shares — an estimated $726K sold.

Perceptive Advisors first reported a position in EIGR in Q1 2016 and held it in 24 quarters. The position peaked at $2.2M in Q4 2017. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

Perceptive Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Perceptive Advisors sold 4,663 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $726K.
Perceptive Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2016 and held it in 24 quarters.
Perceptive Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $2.2M in Q4 2017.
94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.